• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006

Introduction to 1,2,3,4-tetrahydro-6-methyl-Quinoxaline (CAS No. 6639-93-6)

1,2,3,4-tetrahydro-6-methyl-Quinoxaline (CAS No. 6639-93-6) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the quinoxaline family, which is known for its diverse biological activities and potential therapeutic applications. The structure of 1,2,3,4-tetrahydro-6-methyl-Quinoxaline consists of a six-membered ring fused with a five-membered ring, with a methyl group attached to the quinoxaline nucleus. This unique structure confers the compound with several interesting properties that make it a valuable candidate for various research and development activities.

The chemical formula of 1,2,3,4-tetrahydro-6-methyl-Quinoxaline is C₉H₁₁N₂, and its molecular weight is 147.19 g/mol. The compound is typically synthesized through a series of well-documented chemical reactions, including the condensation of o-phenylenediamine with an appropriate aldehyde or ketone followed by hydrogenation. The resulting product is a colorless to pale yellow solid that is soluble in common organic solvents such as ethanol and dichloromethane.

In recent years, the biological activities of 1,2,3,4-tetrahydro-6-methyl-Quinoxaline have been extensively studied. One of the most notable areas of research has been its potential as an anti-inflammatory agent. Studies have shown that this compound can effectively inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro. This property makes it a promising candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Beyond its anti-inflammatory properties, 1,2,3,4-tetrahydro-6-methyl-Quinoxaline has also been investigated for its neuroprotective effects. Research has demonstrated that this compound can protect neurons from oxidative stress and apoptosis induced by various neurotoxins. These findings suggest that 1,2,3,4-tetrahydro-6-methyl-Quinoxaline may have therapeutic potential in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

In addition to its pharmacological activities, the structural features of 1,2,3,4-tetrahydro-6-methyl-Quinoxaline have made it an attractive scaffold for drug design and development. The quinoxaline nucleus can be readily modified through various functional group manipulations to enhance or modulate its biological activities. For example, the introduction of additional substituents on the quinoxaline ring can improve the compound's solubility and bioavailability, making it more suitable for in vivo studies.

The safety profile of 1,2,3,4-tetrahydro-6-methyl-Quinoxaline has also been evaluated in preclinical studies. Toxicity assessments have shown that this compound exhibits low toxicity at therapeutic concentrations. However, further studies are needed to fully understand its long-term safety and potential side effects in humans.

In conclusion, 1,2,3,4-tetrahydro-6-methyl-Quinoxaline (CAS No. 6639-93-6) is a multifaceted compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its anti-inflammatory and neuroprotective properties make it a valuable candidate for the development of new therapeutic agents. Ongoing research continues to explore the full extent of its biological activities and potential clinical uses.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)